Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, California that focuses on immunotherapy for cancer and immune diseases. Company news frequently highlights progress with its lead ITK inhibitor, soquelitinib, and other clinical-stage candidates in oncology and immunology.
Investors following CRVS news can expect updates on clinical trial milestones, including the registration Phase 3 trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) and randomized trials in atopic dermatitis. Corvus regularly reports interim and final data from Phase 1 and Phase 1b/2 studies, such as results in T cell lymphomas and atopic dermatitis, as well as presentations at major medical meetings like the American Society of Hematology (ASH), the European Society for Medical Oncology (ESMO) and rheumatology congresses.
News releases also cover business updates and financial results, where the company discusses its development strategy for ITK inhibition across cancer and immune diseases, cash runway, and collaborations. Additional announcements may describe progress with ciforadenant in metastatic renal cell cancer, the partner-led mupadolimab program in non-small cell lung cancer, and the Autoimmune Lymphoproliferative Syndrome (ALPS) trial conducted with the National Institute of Allergy and Infectious Diseases.
This CRVS news page aggregates these disclosures so readers can review clinical data announcements, regulatory designations, collaboration updates and corporate events in one place. For those tracking immuno-oncology and immune disease pipelines, Corvus news provides insight into the evolution of its ITK platform and related investigational therapies.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced a conference call on July 30, 2020, at 4:30 pm ET to discuss its business update and second quarter 2020 financial results. The call can be accessed via a toll-free number or by webcast through the investor relations section of their website. Corvus is a clinical-stage biopharmaceutical firm focused on cancer therapies, with key products including ciforadenant, CPI-006, and CPI-818 currently in various clinical trials, including studies for COVID-19 treatment.
Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a Phase 1 study to assess its novel immunotherapy, CPI-006, for treating COVID-19. The trial aims to enroll up to 30 patients with mild to moderate symptoms, following FDA acceptance of its IND application. CPI-006 has shown promise in activating B cells and inducing an antibody response in previous cancer studies. Early results from a patient with advanced cancer and COVID-19 demonstrated high levels of anti-SARS-CoV-2 antibodies and increased memory B cells post-treatment. Corvus plans to evaluate the efficacy and safety of CPI-006 and may pursue broader studies based on results.
BURLINGAME, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals (NASDAQ: CRVS) announced the upcoming presentation of updated data on the Adenosine Gene Signature as a predictive biomarker for patients treated with ciforadenant, an A2A receptor antagonist. This data will be presented at the ASCO20 Virtual Scientific Program from May 29-31, 2020. Findings from the Phase 1b/2 trial in advanced refractory renal cell cancer indicate that CD68 positive myeloid cells may enhance patient selection. The poster presentation will be available for on-demand viewing starting May 29, 2020.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported Q1 2020 business updates and financial results on April 30, 2020. The company achieved significant patient enrollment across three clinical programs. Key developments include positive data for ciforadenant, the Adenosine Gene Signature, and CPI-818. Corvus holds a strong position in targeting the adenosine pathway in oncology. Financially, Corvus reported a net loss of $12.9 million and cash reserves of $68.7 million. The company revised its 2020 operational cash forecast to $29-31 million due to COVID-19 impacts.